Arcus Biosciences develops late-stage immunotherapies, with Domvanalimab and Casdastifan leading the way in targeting large ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio? Summit Therapeutics Inc.

The Medical News Today news team reports on emerging science, cutting-edge research, new treatments, and trending topics in health and medicine. All articles are written by our network of editors ...

Kyiv has struggled for months to counter the highly-destructive bombs which have been laying waste to the eastern part of the country ...